Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications.

Martinez-Ciarpaglini C, Fleitas-Kanonnikoff T, Gambardella V, Llorca M, Mongort C, Mengual R, Nieto G, Navarro L, Huerta M, Rosello S, Roda D, Tarazona N, Navarro S, Ribas G, Cervantes A.

ESMO Open. 2019 May 27;4(3):e000470. doi: 10.1136/esmoopen-2018-000470. eCollection 2019.

2.

Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.

Sclafani F, Wilson SH, Cunningham D, Gonzalez De Castro D, Kalaitzaki E, Begum R, Wotherspoon A, Capdevila J, Glimelius B, Roselló S, Thomas J, Tait D, Brown G, Oates J, Chau I.

Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32507. [Epub ahead of print]

PMID:
31199501
3.

Improving tumor budding evaluation in colon cancer by extending the assessment area in colectomy specimen.

Martinez-Ciarpaglini C, Fernandez-Sellers C, Tarazona N, Roselló S, Huerta M, Roda D, Mongort C, Ferrández A, Navarro S, Cervantes A.

Histopathology. 2019 May 13. doi: 10.1111/his.13900. [Epub ahead of print]

PMID:
31081121
4.

Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma.

Gambardella V, Fleitas T, Tarazona N, Cejalvo JM, Gimeno-Valiente F, Martinez-Ciarpaglini C, Huerta M, Roselló S, Castillo J, Roda D, Cervantes A.

Ann Oncol. 2019 May 2. pii: mdz143. doi: 10.1093/annonc/mdz143. [Epub ahead of print]

PMID:
31046106
5.

FT-MIR determination of taste-related compounds in tomato: a high throughput phenotyping analysis for selection programs.

Ibáñez G, Valcárcel M, Cebolla-Cornejo J, Roselló S.

J Sci Food Agric. 2019 Aug 30;99(11):5140-5148. doi: 10.1002/jsfa.9760. Epub 2019 May 24.

PMID:
31006865
6.

Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer.

Baguena G, Pellino G, Frasson M, Roselló S, Cervantes A, García-Granero A, Giner F, García-Granero E.

Dis Colon Rectum. 2019 Jun;62(6):684-693. doi: 10.1097/DCR.0000000000001367.

PMID:
30839315
7.

NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.

Gambardella V, Gimeno-Valiente F, Tarazona N, Martinez-Ciarpaglini C, Roda D, Fleitas T, Tolosa P, Cejalvo JM, Huerta M, Roselló S, Castillo J, Cervantes A.

Clin Cancer Res. 2019 Mar 1;25(5):1639-1649. doi: 10.1158/1078-0432.CCR-18-2421. Epub 2018 Nov 30.

PMID:
30504425
8.

Maintenance with single agent bevacizumab fails to improve disease-control in metastatic colorectal cancer.

Roselló S, Borrás R, Cervantes A.

Hepatobiliary Surg Nutr. 2018 Oct;7(5):395-398. doi: 10.21037/hbsn.2018.08.02. No abstract available.

9.

Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).

Maurel J, Sánchez-Cabús S, Laquente B, Gaba L, Visa L, Fabregat J, Povés I, Roselló S, Díaz-Beveridge R, Martín-Richard M, Rodriguez J, Sabater L, Conill C, Cambray M, Reig A, Ayuso JR, Valls C, Ferrández A, Bombí JA, Ginés A, García-Albéniz X, Fernández-Cruz L.

Cancer Chemother Pharmacol. 2018 Dec;82(6):935-943. doi: 10.1007/s00280-018-3682-9. Epub 2018 Sep 17.

PMID:
30225601
10.

Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression.

Martinez-Ciarpaglini C, Oltra S, Roselló S, Roda D, Mongort C, Carrasco F, Gonzalez J, Santonja F, Tarazona N, Huerta M, Espí A, Ribas G, Ferrández A, Navarro S, Cervantes A.

Mod Pathol. 2019 Feb;32(2):306-313. doi: 10.1038/s41379-018-0124-5. Epub 2018 Sep 11.

PMID:
30206410
11.

Borderline resectable pancreatic cancer. Challenges and controversies.

Sabater L, Muñoz E, Roselló S, Dorcaratto D, Garcés-Albir M, Huerta M, Roda D, Gómez-Mateo MC, Ferrández-Izquierdo A, Darder A, Cervantes A.

Cancer Treat Rev. 2018 Jul;68:124-135. doi: 10.1016/j.ctrv.2018.06.006. Epub 2018 Jun 13. Review.

PMID:
29957372
12.

Neoadjuvant score in locally advanced rectal cancer: integrating downstaging in risk assessment and looking for new valuable end points.

Roselló S, Cervantes A.

Ann Oncol. 2018 Jul 1;29(7):1493-1494. doi: 10.1093/annonc/mdy182. No abstract available.

PMID:
29767693
13.

Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.

Roselló S, Blasco I, García Fabregat L, Cervantes A, Jordan K; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv260. doi: 10.1093/annonc/mdy158. No abstract available.

PMID:
29741578
14.

Influence of controlled deficit irrigation on tomato functional value.

Martí R, Valcárcel M, Leiva-Brondo M, Lahoz I, Campillo C, Roselló S, Cebolla-Cornejo J.

Food Chem. 2018 Jun 30;252:250-257. doi: 10.1016/j.foodchem.2018.01.098. Epub 2018 Feb 2.

PMID:
29478538
15.

The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision.

Roselló S, Papaccio F, Roda D, Tarazona N, Cervantes A.

Cancer Treat Rev. 2018 Feb;63:156-171. doi: 10.1016/j.ctrv.2018.01.001. Epub 2018 Jan 11. Review.

PMID:
29407455
16.

Integrating Downstaging in the Risk Assessment of Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: Validation of Valentini's Nomograms and the Neoadjuvant Rectal Score.

Roselló S, Frasson M, García-Granero E, Roda D, Jordá E, Navarro S, Campos S, Esclápez P, García-Botello S, Flor B, Espí A, Masciocchi C, Valentini V, Cervantes A.

Clin Colorectal Cancer. 2018 Jun;17(2):104-112.e2. doi: 10.1016/j.clcc.2017.10.014. Epub 2017 Oct 28.

PMID:
29162332
17.

Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.

Sclafani F, Brown G, Cunningham D, Wotherspoon A, Mendes LST, Balyasnikova S, Evans J, Peckitt C, Begum R, Tait D, Tabernero J, Glimelius B, Roselló S, Thomas J, Oates J, Chau I.

Br J Cancer. 2017 Nov 7;117(10):1478-1485. doi: 10.1038/bjc.2017.320. Epub 2017 Sep 21.

18.

Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.

Roselló S, Blasco I, García Fabregat L, Cervantes A, Jordan K; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv100-iv118. doi: 10.1093/annonc/mdx216. No abstract available.

PMID:
28881914
19.

Polyphenol and l-ascorbic acid content in tomato as influenced by high lycopene genotypes and organic farming at different environments.

Martí R, Leiva-Brondo M, Lahoz I, Campillo C, Cebolla-Cornejo J, Roselló S.

Food Chem. 2018 Jan 15;239:148-156. doi: 10.1016/j.foodchem.2017.06.102. Epub 2017 Jun 20.

PMID:
28873552
20.

Simultaneous determination of main phenolic acids and flavonoids in tomato by micellar electrokinetic capillary electrophoresis.

Martí R, Valcárcel M, Herrero-Martínez JM, Cebolla-Cornejo J, Roselló S.

Food Chem. 2017 Apr 15;221:439-446. doi: 10.1016/j.foodchem.2016.10.105. Epub 2016 Oct 24.

PMID:
27979225
21.

SEOM Clinical Guideline of localized rectal cancer (2016).

González-Flores E, Losa F, Pericay C, Polo E, Roselló S, Safont MJ, Vera R, Aparicio J, Cano MT, Fernández-Martos C.

Clin Transl Oncol. 2016 Dec;18(12):1163-1171. doi: 10.1007/s12094-016-1591-0. Epub 2016 Nov 30.

22.

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.

Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, Lin K, Yan Y, Patel P, Baselga J, Tabernero J, Cervantes A.

Cancer Discov. 2017 Jan;7(1):102-113. doi: 10.1158/2159-8290.CD-16-0512. Epub 2016 Nov 21. Erratum in: Cancer Discov. 2018 Nov;8(11):1490.

23.

Erratum to «Non-surgical treatment of localized rectal cancer is an experimental option».

Roselló S, Cervantes A.

Cir Esp. 2016 Dec;94(10):617. doi: 10.1016/j.ciresp.2016.07.003. Epub 2016 Sep 22. English, Spanish. No abstract available.

PMID:
27665962
24.

Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment.

Llorca-Cardeñosa MJ, Fleitas T, Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini C, Navarro L, Gambardella V, Castillo J, Roselló S, Navarro S, Ribas G, Cervantes A.

Oncotarget. 2016 Sep 27;7(39):63424-63436. doi: 10.18632/oncotarget.11520.

25.

Fruit quality assessment of watermelons grafted onto citron melon rootstock.

Fredes A, Roselló S, Beltrán J, Cebolla-Cornejo J, Pérez-de-Castro A, Gisbert C, Picó MB.

J Sci Food Agric. 2017 Mar;97(5):1646-1655. doi: 10.1002/jsfa.7915. Epub 2016 Sep 2.

26.

Tomato as a Source of Carotenoids and Polyphenols Targeted to Cancer Prevention.

Martí R, Roselló S, Cebolla-Cornejo J.

Cancers (Basel). 2016 Jun 20;8(6). pii: E58. doi: 10.3390/cancers8060058. Review.

27.

Personalised Treatment in Gastric Cancer: Myth or Reality?

Tarazona N, Gambardella V, Huerta M, Roselló S, Cervantes A.

Curr Oncol Rep. 2016 Jul;18(7):41. doi: 10.1007/s11912-016-0525-x. Review.

PMID:
27215435
28.

Non-surgical treatment of localized rectal cancer is an experimental option.

Roselló S, Cervantes A.

Cir Esp. 2016 Jun-Jul;94(6):311-2. doi: 10.1016/j.ciresp.2016.03.003. Epub 2016 Apr 26. English, Spanish. No abstract available. Erratum in: Cir Esp. 2016 Dec;94(10):617.

PMID:
27130214
29.

Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.

Ibarrola-Villava M, Fleitas T, Llorca-Cardeñosa MJ, Mongort C, Alonso E, Navarro S, Burgues O, Vivancos A, Cejalvo JM, Perez-Fidalgo JA, Roselló S, Ribas G, Cervantes A.

Oncotarget. 2016 Apr 19;7(16):22543-55. doi: 10.18632/oncotarget.8002.

30.

Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.

Gambardella V, Tarazona N, Cejalvo JM, Roselló S, Cervantes A.

Expert Opin Drug Metab Toxicol. 2016;12(4):449-56. doi: 10.1517/17425255.2016.1156084. Epub 2016 Mar 10. Review.

PMID:
26895445
31.

Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer.

Ibarrola-Villava M, Llorca-Cardeñosa MJ, Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo JA, Roselló S, Navarro S, Ribas G, Cervantes A.

Oncotarget. 2015 Sep 29;6(29):26935-45. doi: 10.18632/oncotarget.4775.

32.

Quantification of prominent volatile compounds responsible for muskmelon and watermelon aroma by purge and trap extraction followed by gas chromatography-mass spectrometry determination.

Fredes A, Sales C, Barreda M, Valcárcel M, Roselló S, Beltrán J.

Food Chem. 2016 Jan 1;190:689-700. doi: 10.1016/j.foodchem.2015.06.011. Epub 2015 Jun 4.

PMID:
26213027
33.

Extending neoadjuvant chemotherapy in rectal cancer.

Roselló S, Cervantes A.

Lancet Oncol. 2015 Aug;16(8):880-1. doi: 10.1016/S1470-2045(15)00092-3. Epub 2015 Jul 14. No abstract available.

PMID:
26187752
34.

EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.

Roda D, Castillo J, Telechea-Fernández M, Gil A, López-Rodas G, Franco L, González-Rodríguez P, Roselló S, Pérez-Fidalgo JA, García-Trevijano ER, Cervantes A, Zaragozá R.

PLoS One. 2015 Jun 25;10(6):e0130543. doi: 10.1371/journal.pone.0130543. eCollection 2015.

35.

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.

Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F.

Br J Cancer. 2015 Jun 9;112(12):1874-81. doi: 10.1038/bjc.2015.144. Epub 2015 May 19.

36.

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argilés G, Skartved NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J.

Cancer Discov. 2015 Jun;5(6):598-609. doi: 10.1158/2159-8290.CD-14-1432. Epub 2015 May 11.

37.

Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary.

Marinello FG, Frasson M, Baguena G, Flor-Lorente B, Cervantes A, Roselló S, Espí A, García-Granero E.

Dis Colon Rectum. 2015 Jun;58(6):556-65. doi: 10.1097/DCR.0000000000000349.

PMID:
25944427
38.

Fast simultaneous determination of prominent polyphenols in vegetables and fruits by reversed phase liquid chromatography using a fused-core column.

Martí R, Valcárcel M, Herrero-Martínez JM, Cebolla-Cornejo J, Roselló S.

Food Chem. 2015 Feb 15;169:169-79. doi: 10.1016/j.foodchem.2014.07.151. Epub 2014 Aug 7.

PMID:
25236213
39.

Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment.

Martínez MT, González I, Tarazona N, Roselló S, Saiz R, Sanmartín A, Martínez-Agulló Á, Caballero A, Mas P, Franco J, Martínez-Jabaloyas J, García-Callejo J, Martín V, Navarro J, Teruel A, Lluch A, Chirivella I.

Clin Transl Oncol. 2015 Feb;17(2):167-72. doi: 10.1007/s12094-014-1209-3. Epub 2014 Aug 7.

PMID:
25100066
40.

Prognostic implications of the standardized study of resection margins in pancreatic cancers.

Sabater L, Gómez-Mateo Mdel C, López-Sebastián J, Muñoz-Forner E, Morera-Ocón F, Cervantes A, Roselló S, Camps-Vilata B, Ferrández A, Ortega J.

Cir Esp. 2014 Oct;92(8):532-8. doi: 10.1016/j.ciresp.2013.07.014. Epub 2014 May 28. English, Spanish.

PMID:
24878428
41.

Step-along power vector method for astigmatic wavefront propagation.

Roselló S, Thibos L, Micó V.

Ophthalmic Physiol Opt. 2014 May;34(3):295-308. doi: 10.1111/opo.12120.

PMID:
24754428
42.

Current questions for the treatment of advanced gastric cancer.

Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA.

Cancer Treat Rev. 2013 Feb;39(1):60-7. doi: 10.1016/j.ctrv.2012.09.007. Epub 2012 Oct 25. Review.

PMID:
23102520
43.

Test-retest reliability of Family L.I.F.E. (Looking Into Family Experiences): an occupation-based assessment.

Honaker D, Rosello SS, Candler C.

Am J Occup Ther. 2012 Sep-Oct;66(5):617-20. doi: 10.5014/ajot.2012.004002.

PMID:
22917128
44.

High efficiency joint CZE determination of sugars and acids in vegetables and fruits.

Cebolla-Cornejo J, Valcárcel M, Herrero-Martínez JM, Roselló S, Nuez F.

Electrophoresis. 2012 Aug;33(15):2416-23. doi: 10.1002/elps.201100640.

PMID:
22887163
45.

Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.

Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Roselló S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Maños L, Pérez-Fidalgo JA, Fingert H, Baselga J, Tabernero J.

Clin Cancer Res. 2012 Sep 1;18(17):4764-74. doi: 10.1158/1078-0432.CCR-12-0571. Epub 2012 Jul 2.

46.

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.

Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodríguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, Hsu K, Calvo E, Roselló S, Langdon RB, Baselga J.

Clin Cancer Res. 2011 Oct 1;17(19):6304-12. doi: 10.1158/1078-0432.CCR-10-3336. Epub 2011 Aug 2.

47.

Evaluation of genotype and environment effects on taste and aroma flavor components of Spanish fresh tomato varieties.

Cebolla-Cornejo J, Roselló S, Valcárcel M, Serrano E, Beltrán J, Nuez F.

J Agric Food Chem. 2011 Mar 23;59(6):2440-50. doi: 10.1021/jf1045427. Epub 2011 Feb 23.

PMID:
21344884
48.

Evaluation of the genotype, environment and their interaction on carotenoid and ascorbic acid accumulation in tomato germplasm.

Roselló S, Adalid AM, Cebolla-Cornejo J, Nuez F.

J Sci Food Agric. 2011 Apr;91(6):1014-21. doi: 10.1002/jsfa.4276. Epub 2011 Feb 15.

49.

Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer.

Frasson M, Garcia-Granero E, Roda D, Flor-Lorente B, Roselló S, Esclapez P, Faus C, Navarro S, Campos S, Cervantes A.

Cancer. 2011 Jul 15;117(14):3118-25. doi: 10.1002/cncr.25866. Epub 2011 Jan 24.

50.

Molecular and functional characterization of mouse S5D-SRCRB: a new group B member of the scavenger receptor cysteine-rich superfamily.

Miró-Julià C, Roselló S, Martínez VG, Fink DR, Escoda-Ferran C, Padilla O, Vázquez-Echeverría C, Espinal-Marin P, Pujades C, García-Pardo A, Vila J, Serra-Pagès C, Holmskov U, Yélamos J, Lozano F.

J Immunol. 2011 Feb 15;186(4):2344-54. doi: 10.4049/jimmunol.1000840. Epub 2011 Jan 7.

Supplemental Content

Loading ...
Support Center